Next-Generation Oncology Solutions Inspired by Nature

What we do


Flavocure Biotech Inc. aims to be a leader in transforming natural products into new cures for patients.

The company has discovered several promising new drug candidates. In collaboration with some of the most prestigious research institutions in the world, Flavocure is advancing these candidates through clinical research. Preliminary data indicate that Flavocure’s drug candidates possess activity against known driver mutations and targets implicated in cancer.

Caflanone is Flavocure’s lead drug candidate and received FDA Orphan Drug Designation in 2019 for pancreatic cancer. 

In addition to pancreatic cancer, Flavocure’s drug candidates have demonstrated activity in a variety of cancers, including Glioblastoma (an aggressive form of brain cancer), Acute Myeloid Leukemia, and Multiple Myeloma.

Flavocure Biotech

Oncology Pipeline

Developmental Stage
Worldwide Rights
Research Partners
CSF1-R & Kras
Pancreatic Cancer
IND ready
FDA-ORPHAN Drug Designation
new logo1
new logo1
FDA-ORPHAN Drug Designation
new logo1

In the US, SEER reported pancreatic cancer as the 11th most common cancer with 60,430 new cases and 48,220 deaths in 2022. Pancreatic cancer statistics highlight a dire need for transformative therapies for this lethal disease

2022 US Pancreatic Cancer Statistics

Glioblastoma or brain cancer is considered a very dire prognosis for patients. In the US, SEER reported cancers of the brain and other nervous systems to be 16th most common cancer with 25,051 new cases and 18,280 deaths in 20222.

2022 Brain and other nervous system cancer statistics

Myeloma is a type of blood cancer that develops from plasma cells, a type of white blood cells. In the US, SEER reported Myeloma to be the 14th most common cancer with 34,470 new cases and 12,640 deaths in 2022.

2022 Myeloma statistics

AML is a type of blood cancer that starts in the blood forming cells of the bone marrow. In the US SEER reported AML to be relatively rare cancer with 20,050 new cases and 11,540 deaths in 2022 

2022 AML statistics

Our Team

Henry Lowe PhD

Henry C. Lowe, PhD

Executive Chairman/Founder
Ngeh Toyang PhD

Ngeh J. Toyang, PhD

CEO/Co-Founder & Interim CSO
David Brooks

David Brooks, MD, PhD

Interim CMO
Dr Thomas Lang

Thomas Lang, PhD

VP, Quality and Regulatory Affairs

Douglas Liu

Chief Financial Officer
Henry Lowe PhD

Henry C. Lowe, PhD

Executive Chairman/Founder/Director
Ngeh Toyang PhD

Ngeh J. Toyang, PhD

justin grant

Justin Grant, PhD

Tony Deasey

Anthony Deasey

Chief Financial Advisor (CEO, 2nd Stage Bio-Advisors, LLC)
Saurabh Sewak

Saurabh Sewak, PhD

Business Advisor (CEO, Sewaa Strategies, LLC)
Thomas Woolf

Thomas Woolf, PhD

Scientific Advisor


Latest News


Subscribe to Receive News from Flavocure Biotech

Join our Mailing list!

Get all latest news from Flavocure Biotech